Oculogica

Oculogica is a medical technology company that has developed the EyeBOX, an FDA-cleared device that aids in the diagnosis of concussions. The EyeBOX utilizes eye-tracking technology and a proprietary algorithm to measure abnormalities in eye movements caused by potential concussions. It is the first objective, baseline-free diagnostic tool for concussions, taking less than four minutes to complete.

The non-invasive EyeBOX test does not rely on the patient's literacy level and can be used for both pediatric and adult patients aged five to 67 years, regardless of the activity that caused the injury. During the test, patients watch a short video while the device measures their eye movements and provides a "BOX score" that correlates with the absence or presence of a concussion.

Oculogica launched the latest generation of the EyeBOX device in March 2022, which is lightweight, battery-operated, and portable, making it suitable for use in clinical and sports settings. The company has conducted multi-center studies, and the device has been clinically validated and featured in numerous peer-reviewed medical journals.

In December 2021, Oculogica secured FDA 510(k) clearance for the EyeBOX Model EBX-4, a Class II device. The company's initial EyeBOX device received De Novo classification from the FDA in 2018, setting a precedent for concussion diagnostics.

Key customers and partnerships

The EyeBOX technology is being utilized by leading healthcare institutions such as the Mayo Clinic, Midwest Orthopaedics at Rush University, Children's Hospital of Philadelphia, the University of Colorado, and the Minneapolis Clinic of Neurology.